A record of what Motilal Oswal Analysis said publicly, with the source. Not advice.
Pending — not yet graded
“Maintains a neutral rating on Dr. Reddy's Laboratories. While the semaglutide opportunity in Canada and other markets is expected to offset the reduction in generic-Revlimid business from 3QFY26, the strong contribution from generic-Revlimid in FY25 leads to an expected 3% compounded decline in earnings over FY25-27.”
Motilal Oswal Analysis’s track record (trackable calls only): 453 graded calls · 95% CI 36–45%
Dr. Reddy's LaboratoriesNeutralCalled 24 Jul 2025
This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.
Read the original articleSee Motilal Oswal Analysis’s full track record